FDA recalls tainted supplements

The agency recalls products marketed as sexual enhancement, weight-loss and muscle-gain supplements because of threats to consumer safety. On Nov. 9, RockHard Labs of Atlanta voluntary recalled RockHard Weekend for erectile dysfunction, which FDA said contained the undeclared ingredient sulfoaildenafil. FDA recently warned against use of Imulsaria's Stiff Nights, which it said contains the same active ingredient (1"The Tan Sheet" Nov. 9, 2009, In Brief). The agency also announced Nov. 12 that Westminster, Calif.-based GMP Herbal Products voluntarily recalls Pai You Guo, labeled as a weight-loss supplement, in which FDA found the appetite suppressant sibutramine, contained in the Rx obesity drug Meridia, and the suspected carcinogen phenolphthalein (2"The Tan Sheet" Nov. 16, 2009, In Brief). Finally, FDA said Nov. 12 that a number of products made by Oviedo, Fla.-based IDS Sports, including Bromodrol and Ripped Tabs TR, contain steroids and are recalled. Steroids sold as "supplements" is an area of particular concern within the supplement industry (3"The Tan Sheet" Oct. 26, 2009)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Ocaliva: Still No Clarity On Why EU Court Opposed Revocation Of Approval

 

Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By 

We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.

Brazil Pilots Digital Drug Pack Inserts

 

A new pilot aims to take Brazil closer to ‘digital transformation.’

More from Pink Sheet

EMA’s PRIME Scheme Explored: Growing Designations - But Are Accelerated Assessments Slipping?

 

While the first six months of the year saw eight new drugs targeting a range of diseases enter the European Medicines Agency’s priority medicines scheme, and three PRIME-designated treatments go on to win EU marketing approval, use of the accelerated assessment mechanism appears to be limited.

Global Pharma Guidance Tracker - June 2025

 

Stay up to date on regulatory guidelines from around the world with the Pink Sheet’s Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

US FDA’s CRL Release More Incremental Than ‘Radical’ Transparency

 

The transparency initiative collects CRLs already made public in approval packages on its drugs@fda site to post on the openFDA public portal.